Navigation Links
Fractional dose of scarce meningitis vaccine may be effective in outbreak control
Date:12/5/2008

One fifth of the standard dose of a commonly used meningitis vaccine may be as effective as using the full dose. This new finding should allow scarce vaccine resources to be stretched further, especially during epidemics in Africa.

In a study initiated by the Norwegian Institute of Public Health, together with Epicentre (the research arm of Doctors Without Borders/Mdecins Sans Frontires), and Mbarara University of Science and Technology in Uganda, immune responses in patients receiving smaller doses of a meningitis vaccine were found to be comparable to a full dose.

In 2004, a randomized clinical trial of 750 healthy volunteers (2-19 years old) took place in Uganda. Their immune response, assessed by serum bactericidal activity (SBA), was measured for 1/5 and 1/10 doses compared to a full dose. SBA response and safety/tolerability using 1/5 dose were comparable to a full dose for three serogroups (A, Y, W135), but not a fourth (C).

In view of the current shortage of meningococcal vaccines for Africa, the use of 1/5 fractional doses should be considered as an alternative in mass vaccination campaigns. The study's findings contributed to a 2007 WHO recommendation that a fractional dosing strategy be utilized in the event of severe vaccine shortages during a meningitis epidemic.


'/>"/>

Contact: Media Contact
julie.johansen@fhi.no
Norwegian Institute of Public Health
Source:Eurekalert

Page: 1

Related biology news :

1. New discovery on role of vital protein that fights meningitis
2. Possible hepatitis C vaccine
3. Study by Pittsburgh researchers identifies possible vaccine target for chlamydia
4. New nanoparticle vaccine is more effective but less expensive
5. Flu vaccine in painless skin patches under development at Emory, Georgia Tech with NIH grants
6. Influenza vaccine causes weaker immune response for children of rural Gabon than in semi-urban areas
7. An Alzheimers vaccine?
8. Penn researchers find monkeys able to fend off AIDS-like symptoms with enhanced HIV vaccine
9. CWRU School of Medicine has evidence vaccine against malaria will reduce disease
10. HIV isolate from Kenya provides clues for vaccine design
11. Iowa State researchers look for smaller, cheaper, 1-dose vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/7/2017)... , March 7, 2017 Brandwatch , the ... by The Prince,s Trust to uncover insights to support ... The Trust. The UK,s leading youth charity will be ... campaign results and get a better understanding of the topics and ... ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , ... March 23, 2017 , ... ... material that exhibits both viscous and elastic characteristics when deformed, which is identical ... exhibits properties to gently absorb compressive forces and return to its natural state ...
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseqâ„¢ ... developed with input from industry experts to ...
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
Breaking Biology Technology: